Anika Therapeutics, Inc.
ANIK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | -$0 |
| % Growth | -1.4% | 7.8% | 2,128.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 56% | 50.9% | 56.1% | -1,749.2% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -3% | -9.8% | -10.3% | -2,056.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -8.4% | -14.1% | -18.6% | 1,695% |
| EPS Diluted | -0.16 | -0.28 | -0.34 | -1.5 |
| % Growth | 42.9% | 17.6% | 77.3% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | $0 |